# US 2026/0098089 A1 · Antagonist anti-cd7 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098089 A1
- Document ID: US20260098089A1
- Status: Published application
- Kind: A1
- Application number: 19/322,242
- Filed: 2025-09-08
- Published: 2026-04-09
- Earliest claimed: 2019-04-18
- Assignees: Kymab Limited
- Applicants: Kymab Limited
- Inventors: E-Chiang LEE; Gwenoline BORHIS; Cassandra VAN KRINKS; Lucy HEPBURN; Luke BAYLISS; Miha KOSMAC
- Web page: https://patentgrep.com/patent/US20260098089A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to Cluster of Differentiation 7 (CD7) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.

## Claims

### Claim 1

An antibody or fragment comprising a binding site which specifically binds to CD7 (Cluster of Differentiation 7), wherein the binding site comprises a VH domain that is encoded by a nucleotide sequence that is derived from the recombination of a human VH gene segment, DH gene segment and JH gene segment, wherein the VH gene segment is IGHV3-15.

### Claim 2 (depends on 1)

The antibody or fragment according to claim 1, wherein the DH gene segment is a human gene segment selected from IGHD3-9 and IGH6-19 and/or wherein the JH gene segment is a human gene segment selected from IGHJ6 and IGHJ4.

### Claim 3 (depends on 1)

The antibody or fragment of claim 1 comprising
(a) a VH domain which comprises a CDRH3 sequence of an antibody selected from G09 and E04 or said sequence comprising 3, 2 or 1 amino acid substitution(s); and optionally the VH domain comprises a CDRH1 sequence of said selected antibody or said CDRH1 sequence comprising 3, 2 or 1 amino acid substitution(s); or
(b) a VH domain which comprises a CDRH3 sequence of an antibody selected from G09 and E04 or said CDRH3 sequence comprising 3, 2 or 1 amino acid substitution(s); and optionally comprises a CDRH2 sequence of said selected antibody or said CDRH2 sequence comprising 3, 2 or 1 amino acid substitution(s); or
(c) a VH domain which comprises a CDRH1, 2 and 3 sequence of an antibody selected from G09 and E04 or said sequence comprising 3, 2 or 1 amino acid substitution(s); or
(d) a CDRH3 sequence selected from SEQ ID NO: 3, 6, 63 and 66.

### Claim 4 (depends on 1)

The antibody or fragment of claim 1, wherein the binding site comprises a VH domain that comprises the amino acid sequence of a VH domain of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto.

### Claim 5

(canceled)

### Claim 6

An antibody or fragment comprising a binding site which specifically binds to CD7, wherein the binding site comprises a VL domain that is encoded by a nucleotide sequence that is derived from the recombination of a human VL gene segment and JL gene segment, wherein the VL gene segment is IGKV1D-39.

### Claim 7 (depends on 6)

The antibody or fragment according to claim 6, wherein the VL is a VK and the JL gene segment is a human gene segment IGKJ4.

### Claim 8 (depends on 1)

The antibody or fragment of claim 1, comprising
(e) a VL domain which comprises a CDRL3 sequence selected from SEQ ID NO: 13 and 16, or said selected CDRL3 sequence comprising 3, 2 or 1 amino acid substitution(s);
(f) a VL domain which comprises a CDRL3 (and optionally a CDRH3) sequence of antibody selected from G09 E04 or said sequence(s) each comprising 3, 2 or 1 amino acid substitution(s) and optionally the VL domain comprises a CDRL1 sequence of antibody G09 or said CDR1 sequence(s) each comprising 3, 2 or 1 amino acid substitution(s); or
(g) a VL domain which comprises a CDRL3 (and optionally a CDRH3) sequence of antibody selected G09 or said CDR3 sequence(s) each comprising 3, 2 or 1 amino acid substitution(s); and optionally a CDRL2 sequence of antibody G09 or said CDR2 sequence(s) each comprising 3, 2 or 1 amino acid substitution(s).

### Claim 9 (depends on 1)

The antibody or fragment according to claim 1 which comprises
(h) the heavy chain amino acid sequence of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto; and/or
(i) the light chain amino acid sequence of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto.

### Claim 10 (depends on 1)

The antibody or fragment according to claim 1,
wherein the binding site comprises a VL domain that comprises the amino acid sequence of a VL domain of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

The antibody or fragment according to claim 1,
wherein the antibody or fragment comprises a human constant region that comprises the amino acid sequence of SEQ ID NO: 88, 90, 92, 94 or 96 (eg, SEQ ID NO: 88).

### Claim 14 (depends on 1)

The antibody or fragment according to claim 1 further comprising an antigen-binding site that specifically binds another target antigen.

### Claim 15 (depends on 1)

A method for treating or preventing a CD7-mediated disease or condition in a subject, comprising administering the anti-CD7 antibody or fragment of claim 1 to the subject.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein the antibody or fragment is administered to the subject simultaneously or sequentially with chemotherapy or an immune checkpoint inhibitor.

### Claim 18 (depends on 1)

A combination comprising the anti-CD7 antibody or fragment of claim 1 and a chemotherapeutic.

### Claim 19 (depends on 1)

A method of treating leukaemia in a human comprising administering the anti-CD7 antibody or fragment of claim 1, wherein the antibody, fragment or combination is administered to the human with an antagonist of human CD5, CD14 or CD19.

### Claim at position 19

20-22. (canceled)

### Claim 23 (depends on 1)

A pharmaceutical composition comprising an antibody, fragment or combination as defined in claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 24 (depends on 1)

A nucleic acid that
(j) encodes a VH domain of an antibody or fragment as defined in claim 1;
(k) encodes (i) a VH domain comprising the amino acid sequence of a VH domain of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto; and/or (ii) a VL domain comprising the amino acid sequence of a VL domain of an antibody selected from G09 and E04; or an amino acid that is at least 70% identical thereto;
(l) comprises a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 10; and/or a nucleotide sequence that is at least 70% identical to the sequence of SEQ ID NO: 20;
(m) encodes a heavy chain of an antibody or fragment as defined in claim 1;
(n) encodes (i) a heavy chain comprising an amino acid sequence that is at least 70% identical to SEQ ID NO: 7 and/or (ii) a light chain comprising an amino acid sequence that is at least 70% identical to SEQ ID NO: 17; or
(o) comprises a nucleotide sequence that is at least 70% identical to a heavy chain sequence selected of an antibody selected from G09 and E04; and/or a nucleotide sequence that is at least 70% identical to a sequence selected of an antibody selected from G09 and E04.

### Claim 25

(canceled)

### Claim 26 (depends on 24)

A host cell comprising the nucleic of claim 24.

### Claim 27 (depends on 1)

A method of diagnosing a CD7-mediated disease or condition in a subject, the method comprising combining the antibody or fragment of claim 1 with an isolated blood or serum sample and determining that cells comprised by the sample are specifically bound by the antibody or fragment.

### Claim 28 (depends on 1)

An in vitro assay for detecting CD7-positive cells in a sample, the assay comprising combining antibody or fragment of claim 1 with an isolated blood or serum sample and determining that cells comprised by the sample are specifically bound by the antibody or fragment.
